Home > Health > Breaking News from AHA - MIRACL

Breaking News from AHA - MIRACL

Added: (Fri Nov 24 2000)

Pressbox (Press Release) - LIPITOR TRIAL DEMONSTRATES REDUCTION IN EVENTS
FOR ACUTE CORONARY SYNDROME PATIENTS

Immediate post-event treatment with Lipitor reduced future
events within four months


New Orleans, Louisiana, November 15, 2000-Pfizer Inc reported today that a new clinical study showed patients treated with LIPITORÒ (atorvastatin calcium) following an acute coronary syndrome (ACS) experienced fewer subsequent events than those treated with placebo. Results of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study were presented here today at the 73rd Scientific Sessions of the American Heart Association.

The study involved 3,086 patients who received either atorvastatin (80 mg daily) or placebo for 16 weeks, both with dietary education and counseling, initiated between 24 to 96 hours of an ACS, also known as mild heart attack or severe cardiac chest pain. Patients ordinarily experience a high rate of death and secondary ischemic events within this early period.

Study participants treated with atorvastatin experienced a significant reduction (16%; p=0.048) in the risk of the primary combined endpoint of death, non-fatal acute MI (heart attack), cardiac arrest with resuscitation, or recurrent symptomatic myocardial ischemia requiring emergency rehospitalization. The reduction in the combined endpoint was primarily due to a favorable effect of atorvastatin on recurrent symptomatic myocardial ischemia, or oxygen deprivation to the heart resulting in chest tightness, which was reduced by 26% (p=0.02). In addition, the incidence of stroke was significantly reduced in the atorvastatin group compared with the placebo group.

Previous trials with other statins have established the benefit of conventional lipid-lowering therapy in reducing death and non-fatal events in patients with stable coronary heart disease over periods of years. However, the previous trials excluded patients who had sustained a recent ACS, a group that is at a high risk of having a subsequent event. MIRACL is the first trial to demonstrate that the clinical benefit of aggressive lipid-lowering therapy can be achieved within the critical months (16 weeks) following an acute coronary event.

"MIRACL demonstrated that intensive treatment with atorvastatin, begun immediately after an acute coronary event, produces beneficial effects that are apparent within several weeks," said Gregory Schwartz, M.D., Ph.D., Chief of Cardiology, Denver Veterans Affairs Medical Center, and a Principal Investigator in MIRACL, "providing evidence that the addition of intensive lipid-lowering therapy to the standard of care may help improve the outcomes of these patients."

Study participants' LDL-cholesterol levels declined from an average of 123 mg/dL (3.2 mmol/L) at baseline to 72 mg/dL (1.9 mmol/L) during treatment with atorvastatin. Therefore, treatment lowered LDL-cholesterol to levels well below the current recommended guideline of 100 mg/dL (2.6 mmol/L).

Current hospital treatment practice in this patient population includes a host of medications including combinations of aspirin, heparin, nitrates, and beta blockers, intended to target various aspects of the acute coronary condition. A hospital survey revealed that many coronary heart disease patients admitted for events do not receive lipid-lowering medication. Specifically, only 41% of patients received lipid-lowering medication during hospitalization and only 39% received it at discharge.

"MIRACL found that high-risk patients benefited from receiving aggressive treatment with atorvastatin within 24 to 96 hours following an acute coronary syndrome," said Anders Olsson, M.D., Ph.D., Department of Internal Medicine, Faculty of Health Sciences, University Hospital, Linköping, Sweden, and a MIRACL Principal Investigator. "Not only was high dose atorvastatin effective in reducing cardiovascular events, but the treatment was safe and generally well tolerated."

Atorvastatin is the subject of a broad clinical program consisting of a series of novel studies currently underway that attempt to investigate

unanswered questions in the field of lipid lowering. Nearly 400 clinical trials have been designed for studies with atorvastatin-a large number of which have already been completed. These clinical studies are exploring the possible opportunities for new uses of atorvastatin in clinical practice.

Atorvastatin has been shown in clinical studies to produce reductions in LDL-C of 39% to 60% across the dose range of 10 mg to 80 mg in patients with elevated cholesterol. Reductions in triglycerides of 19% to 37% were reported in clinical trials across the same dose range. Trials assessing the effect of atorvastatin on cardiovascular morbidity and mortality are also underway.

Atorvastatin is indicated as an adjunct to diet to reduce elevated total-C, LDL-C, Apo B, and TG and to increase HDL-C levels in patients with primary hypercholesterolemia and mixed dyslipidemia. The
recommended starting dose of atorvastatin is 10 mg once daily. The dosage range is 10 mg to 80 mg once daily. Atorvastatin is generally well tolerated. Adverse reactions usually have been mild and transient, with fewer than 2% of patients being discontinued from clinical trials due to side effects related to atorvastatin. This rate of discontinuation was comparable to that of placebo. The most frequent adverse effects of atorvastatin are constipation, flatulence, dyspepsia, and abdominal pain. It is recommended that liver function tests be performed prior to and at 12 weeks following both the initiation of therapy and any elevation of dose, and periodically thereafter. Myopathy should be considered in any patient with diffuse myalgias, muscle tenderness or weakness, and/or marked elevation of creatine phosphokinase (CPK).

Pfizer Inc, the world's largest pharmaceutical company, discovers, develops, manufactures, and markets leading prescription medicines for humans and animals, and many of the world's best known over-the-counter brands. This year, Pfizer expects global sales of more than $30 billion and has a research and development budget of $4.7 billion.
# # # #

For full prescribing information, please call Pfizer Medical Information at 1-800-438-1985

Submitted by:
Disclaimer: Pressbox disclaims any inaccuracies in the content contained in these releases. If you would like a release removed please send an email to remove@pressbox.co.uk together with the url of the release.